drugset / Trial / NCT07636226
QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, randomized controlled phase II/III study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.
Timeline
- Start
- 2026-07-30
- Primary completion
- 2028-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |